Published on | 1 year ago
Programmes Climate, Energy, MobilityFor the above mentioned call a total of 133 proposals were submitted.
The breakdown per topic is:
HORIZON-CL5-2023-D6-01-01 (RIA): 16 proposals
HORIZON-CL5-2023-D6-01-02 (RIA): 3 proposals
HORIZON-CL5-2023-D6-01-03 (IA): 10 proposals
HORIZON-CL5-2023-D6-01-04 (RIA): 7 proposals
HORIZON-CL5-2023-D6-01-05 (RIA): 6 proposal
HORIZON-CL5-2023-D6-01-06 (RIA): 29 proposal
HORIZON-CL5-2023-D6-01-07 (RIA): 13 proposals
HORIZON-CL5-2023-D6-01-08 (CSA): 3 proposals
HORIZON-CL5-2023-D6-01-09 (IA): 7 proposals
HORIZON-CL5-2023-D6-01-10 (RIA): 21 proposals
HORIZON-CL5-2023-D6-01-11 (RIA): 11 proposals
HORIZON-CL5-2023-D6-01-12 (RIA): 6 proposals
HORIZON-CL5-2023-D6-01-13 (CSA): 1 proposal
Source: Funding and Tender Portal
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.